ArticleInternational urology and nephrology2025
Metastatic lymph nodes outside the extended lymphadenectomy template correlate with advanced staging but not grading in prostate cancer patients undergoing radical prostatectomy.
Article in International urology and nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to evaluate the impact of metastatic lymph nodes (LNs) outside the extended pelvic lymph node dissection (ePLND) template on oncological outcomes, staging, grading, and concomitant parameters in prostate cancer (PCa) patients undergoing radical prostatectomy (RP).
methodsData from 860 patients with histologically confirmed, non-metastatic PCa who underwent RP between 2012 and 2022 were retrospectively analyzed. All specimens underwent detailed histopathological examination. Preoperative and postoperative clinicopathological data were collected and analyzed. Subgroup associations were evaluated using the Mann-Whitney U test and the Kruskal-Wallis test. Kendall's tau-b coefficient was employed to evaluate the association between two variables. All tests were performed using a two-tailed approach, with a p value of less than 0.05 considered statistically significant for differences between groups. Kaplan-Meier and Cox regression analyses assessed biochemical recurrence (BCR)-free survival based on lymph node invasion (LNI) (pN0 vs. pN1) and the presence of metastatic LNs outside the ePLND template.
resultsOf the 860 patients, 613 underwent modified-ePLND. Among them, 122 (19.9%) were pN1, with 22 patients (18%) having metastatic LNs located outside the classical ePLND template. Patients with LNs beyond the ePLND template exhibited higher clinical T stages (p = 0.016) and a greater percentage of positive biopsy cores (p = 0.008). However, no correlation was observed with Gleason Grading Group (p = 0.491). Kaplan-Meier analysis showed that pN1 patients had higher BCR rates compared to pN0 patients, but this difference did not reach statistical significance (p = 0.174). Similarly, patients with metastatic LNs outside the ePLND template demonstrated a trend toward increased BCR risk, though this was not statistically significant (p = 0.140).
conclusionMetastatic LNs beyond the ePLND template correlate with more advanced tumor staging in PCa. However, they show no association with tumor grading. Their influence on BCR remains inconclusive, likely due to the small number of patients included in the BCR-associated analyses. Extended lymphadenectomy may enhance staging accuracy but must be weighed against the potential for increased surgical morbidity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.